Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.

Claudia Diana WursterPetra SteinackerRené GüntherJan C KochPaul LingorZeljko UzelacSimon WitzelKurt WollinskyBenedikt WinterAlma OsmanovicOlivia Schreiber-KatzRami Al ShweikiAlbert C LudolphSusanne PetriAndreas HermannMarkus Ottonull null

Published in: Journal of neurology (2019)

Diagnostic and monitoring performance of serum NfL measurement seems to differ between SMA subtypes. Unlike to SMA type 1, in adolescent and adult SMA type 2 and 3 patients, neurodegeneration is not reflected by increased NfL levels and short-term therapeutic effects cannot be observed. Long-term follow-up has to be performed to see if even low levels of NfL might be good prognostic markers.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
young adults
mental health
prognostic factors
peritoneal dialysis